BRPI0820749A2 - Derivados de peptídeos mimético de eritropoietina e seu sal farmacêutico, preparação e usos dos mesmos - Google Patents
Derivados de peptídeos mimético de eritropoietina e seu sal farmacêutico, preparação e usos dos mesmosInfo
- Publication number
- BRPI0820749A2 BRPI0820749A2 BRPI0820749-6A BRPI0820749A BRPI0820749A2 BR PI0820749 A2 BRPI0820749 A2 BR PI0820749A2 BR PI0820749 A BRPI0820749 A BR PI0820749A BR PI0820749 A2 BRPI0820749 A2 BR PI0820749A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- peptide derivatives
- pharmaceutical salt
- mimetic peptide
- erythropoietin mimetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101987519A CN101456911A (zh) | 2007-12-12 | 2007-12-12 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
| CN200710198751.9 | 2007-12-12 | ||
| PCT/CN2008/001909 WO2009079910A1 (fr) | 2007-12-12 | 2008-11-24 | Dérivé de peptide mimétique d'érythropoïétine et son sel pharmaceutique, préparation et utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0820749A2 true BRPI0820749A2 (pt) | 2015-06-16 |
| BRPI0820749B1 BRPI0820749B1 (pt) | 2020-11-24 |
| BRPI0820749B8 BRPI0820749B8 (pt) | 2021-05-25 |
Family
ID=40768057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0820749A BRPI0820749B8 (pt) | 2007-12-12 | 2008-11-24 | derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8642545B2 (pt) |
| EP (1) | EP2233504B1 (pt) |
| JP (1) | JP5448099B2 (pt) |
| KR (1) | KR101646929B1 (pt) |
| CN (2) | CN101456911A (pt) |
| AU (1) | AU2008341661B9 (pt) |
| BR (1) | BRPI0820749B8 (pt) |
| CA (1) | CA2708819C (pt) |
| ES (1) | ES2541139T3 (pt) |
| MX (1) | MX2010006436A (pt) |
| RU (1) | RU2493168C2 (pt) |
| TW (1) | TWI419706B (pt) |
| UA (1) | UA102236C2 (pt) |
| WO (1) | WO2009079910A1 (pt) |
| ZA (1) | ZA201003998B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2709648A4 (en) * | 2011-05-19 | 2015-04-08 | Geysen Hendrik M | COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR |
| WO2013158871A1 (en) | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| CN103450348B (zh) * | 2012-05-29 | 2016-03-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种促红细胞生成素模拟肽、其制备方法和用途 |
| CN103536900B (zh) * | 2012-07-16 | 2017-06-16 | 江苏豪森药业集团有限公司 | 含有促红细胞生成素模拟肽的药物组合物 |
| CN103570834A (zh) * | 2012-07-19 | 2014-02-12 | 江苏豪森药业股份有限公司 | 甲氧基聚乙二醇修饰的促红细胞生成素模拟肽衍生物 |
| CN112245586A (zh) * | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| CN104231039A (zh) * | 2013-06-08 | 2014-12-24 | 江苏豪森药业股份有限公司 | 用于合成促红细胞生成素模拟肽衍生物的功能小分子及其制备方法 |
| CN105085653B (zh) * | 2015-08-26 | 2019-01-08 | 天津药物研究院有限公司 | 一种促红细胞生成素模拟肽及其制备方法和应用 |
| CN106608913B (zh) * | 2015-10-22 | 2020-05-05 | 天津药物研究院有限公司 | 一种1，2，3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用 |
| CN106608912B (zh) * | 2015-10-22 | 2019-09-20 | 天津药物研究院有限公司 | 一种脂肪二羧酸偶联的epo模拟肽衍生物及其制备方法和应用 |
| CN105367629B (zh) * | 2015-11-09 | 2019-01-08 | 天津药物研究院有限公司 | 一种促红细胞生成素模拟肽以及其制备方法和用途 |
| CN106928338A (zh) * | 2015-12-31 | 2017-07-07 | 杭州阿德莱诺泰制药技术有限公司 | 促红细胞生成素肽及衍生物和聚合物、制备方法和应用 |
| JP2019532618A (ja) | 2016-07-12 | 2019-11-14 | ヘキサル・アクチェンゲゼルシャフト | 低アセチル化率シアル酸残基を有する糖タンパク質 |
| CN108236717A (zh) * | 2016-12-27 | 2018-07-03 | 江苏豪森药业集团有限公司 | 聚乙二醇连接臂与所修饰多肽药物的偶合物 |
| JP7445978B2 (ja) * | 2018-09-14 | 2024-03-08 | エポメッド株式会社 | 抗エリスロポエチン受容体ペプチド |
| KR102073886B1 (ko) | 2019-05-02 | 2020-02-05 | 주식회사 미래와바다 | 잘피이식용 다공질 패널 |
| CN114601916B (zh) * | 2022-04-12 | 2024-04-16 | 江苏豪森药业集团有限公司 | 一种培化西海马肽注射制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| CA2223833C (en) * | 1995-06-07 | 2010-12-21 | Nicholas C. Wrighton | Compounds and peptides that bind to the erythropoietin receptor |
| EP0964702B1 (en) * | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| ME00673B (me) * | 2000-05-15 | 2011-12-20 | Hoffmann La Roche | Nova farmaceutska smjesa |
| CN1169827C (zh) * | 2001-08-07 | 2004-10-06 | 沈阳三生制药股份有限公司 | 一种增强多肽在体内稳定性药物的生产方法及其应用 |
| AU2004238868B2 (en) * | 2003-05-12 | 2010-01-21 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| ATE428727T1 (de) * | 2003-05-12 | 2009-05-15 | Affymax Inc | Neue, an den erythropoietinrezeptor bindende peptide |
| CN1820024B (zh) * | 2003-05-12 | 2011-06-22 | 阿费麦克斯公司 | 新的聚(乙二醇)修饰的化合物及其用途 |
| CN100362019C (zh) * | 2004-03-02 | 2008-01-16 | 成都生物制品研究所 | 聚乙二醇修饰后具有体内生理活性的重组促红细胞生成素 |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| JP2008519858A (ja) * | 2004-11-11 | 2008-06-12 | アフィーマックス・インコーポレイテッド | エリスロポエチンレセプターに結合する新規ペプチド |
-
2007
- 2007-12-12 CN CNA2007101987519A patent/CN101456911A/zh active Pending
-
2008
- 2008-07-08 TW TW097125651A patent/TWI419706B/zh active
- 2008-11-24 ES ES08865748.1T patent/ES2541139T3/es active Active
- 2008-11-24 EP EP08865748.1A patent/EP2233504B1/en active Active
- 2008-11-24 WO PCT/CN2008/001909 patent/WO2009079910A1/zh not_active Ceased
- 2008-11-24 KR KR1020107014960A patent/KR101646929B1/ko active Active
- 2008-11-24 UA UAA201007321A patent/UA102236C2/uk unknown
- 2008-11-24 MX MX2010006436A patent/MX2010006436A/es active IP Right Grant
- 2008-11-24 JP JP2010537234A patent/JP5448099B2/ja not_active Expired - Fee Related
- 2008-11-24 CA CA2708819A patent/CA2708819C/en active Active
- 2008-11-24 BR BRPI0820749A patent/BRPI0820749B8/pt active IP Right Grant
- 2008-11-24 AU AU2008341661A patent/AU2008341661B9/en active Active
- 2008-11-24 RU RU2010123466/10A patent/RU2493168C2/ru active
- 2008-11-24 CN CN2008800142471A patent/CN101675080B/zh active Active
- 2008-11-24 US US12/747,818 patent/US8642545B2/en active Active
-
2010
- 2010-06-04 ZA ZA2010/03998A patent/ZA201003998B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8642545B2 (en) | 2014-02-04 |
| BRPI0820749B8 (pt) | 2021-05-25 |
| EP2233504A4 (en) | 2011-03-09 |
| JP2011506350A (ja) | 2011-03-03 |
| EP2233504B1 (en) | 2015-04-01 |
| RU2010123466A (ru) | 2012-01-20 |
| CN101675080A (zh) | 2010-03-17 |
| UA102236C2 (uk) | 2013-06-25 |
| EP2233504A1 (en) | 2010-09-29 |
| KR20110025731A (ko) | 2011-03-11 |
| JP5448099B2 (ja) | 2014-03-19 |
| US20100323949A1 (en) | 2010-12-23 |
| CN101456911A (zh) | 2009-06-17 |
| ZA201003998B (en) | 2011-10-26 |
| BRPI0820749B1 (pt) | 2020-11-24 |
| WO2009079910A1 (fr) | 2009-07-02 |
| MX2010006436A (es) | 2010-10-06 |
| RU2493168C2 (ru) | 2013-09-20 |
| AU2008341661B9 (en) | 2013-08-15 |
| TW201002352A (en) | 2010-01-16 |
| CA2708819C (en) | 2018-05-15 |
| AU2008341661B2 (en) | 2013-08-08 |
| CN101675080B (zh) | 2012-07-11 |
| HK1136837A1 (zh) | 2010-07-09 |
| WO2009079910A8 (zh) | 2009-11-19 |
| KR101646929B1 (ko) | 2016-08-09 |
| TWI419706B (zh) | 2013-12-21 |
| AU2008341661A1 (en) | 2009-07-02 |
| ES2541139T3 (es) | 2015-07-16 |
| CA2708819A1 (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0820749A2 (pt) | Derivados de peptídeos mimético de eritropoietina e seu sal farmacêutico, preparação e usos dos mesmos | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| BRPI0915897A2 (pt) | compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos | |
| BR112015003376A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente | |
| BRPI0819909A2 (pt) | anticorpos antimesotelina e usos dos mesmos | |
| BRPI1010621A2 (pt) | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso | |
| BRPI0923283A2 (pt) | conjugados terapêuticos de peptídeo e usos dos mesmos | |
| BRPI1015124A2 (pt) | compostos aromáticos substituídos e usos farmacêuticos dos mesmos | |
| BRPI0919403A2 (pt) | polipeptídeos modificados de eritropoetina animal e seus usos | |
| BRPI0920927A2 (pt) | derivados de azaquinolinona e usos dos mesmos | |
| BRPI1008045A2 (pt) | derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia | |
| BRPI0912356A2 (pt) | compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso | |
| BR112012006404A2 (pt) | derivados de di-hidropteridinona, processo de preparação e uso farmacêutico dos mesmos | |
| IL195491A (en) | Pharmaceutical compositions of tmc278 and processes for their preparation | |
| BR112013015592A8 (pt) | derivados de biciclo-[3.2.1]-octilamida e usos dos mesmos | |
| FR2911604B1 (fr) | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique | |
| BR112013011968A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
| BRPI0715342A2 (pt) | Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos | |
| BRPI0818617A2 (pt) | Uso de derivados de tetrahidroquinolina ou sais deste para a preparação de medicamento para o tratamento de transtornos de estresse pós-traumático e composto ou sal deste. | |
| BRPI0907572A2 (pt) | Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| IL195813A0 (en) | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | |
| BRPI0814599A2 (pt) | Pesticidas e usos dos mesmos | |
| BRPI0818690A2 (pt) | Derivados de quinazolinediona, sua preparação e seus usos terapêuticos. | |
| FR2915199B1 (fr) | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/505 (2006.01), A61K 47/55 (2017.01), A61K |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) |
|
| B25G | Requested change of headquarter approved |
Owner name: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |